Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

CD22-Targeted CAR T Cells Elicit Responses With Acceptable Safety in Heavily Pretreated LBCL

August 3rd 2023

Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

August 1st 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

PD-1 Inhibitors Demonstrate Promise as Salvage Therapy in R/R Extranodal NK/T-cell Lymphoma

July 31st 2023

Amira Marouf, MD, PhD student, describes the nature of a comparative analysis conducted based on propensity score matching, and discussed the main takeaways regarding the efficacy of PD-1 inhibitors for patients with relapsed/refractory ENKTCL.

FDA Issues Complete Response Letter to Denileukin Diftitox for R/R Cutaneous T-cell Lymphoma

July 31st 2023

The FDA has issued a complete response letter to the biologics license application seeking approval of denileukin diftitox for use in patients with relapsed or refractory cutaneous T-cell lymphoma following at least 1 previous systemic therapy.

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27th 2023

The allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Loncastuximab Tesirine BLA Receives Priority Review in China for Relapsed/Refractory DLBCL

July 24th 2023

The China National Medical Products Administration has accepted and granted priority review to the biologics license application seeking the approval of loncastuximab tesirine-lpyl for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma following at least 2 prior lines of systemic therapy.

Dr Falchi on the Use of Glofitamab in R/R LBCL

July 21st 2023

Lorenzo Falchi, MD, iscusses the use of glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.

Epcoritamab Approaches EU Approval for Relapsed/Refractory DLBCL

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending conditional marketing authorization to epcoritamab monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.

PROSPECT Trial Looks to Add Effective Option for Patients With R/R PCNSL

July 13th 2023

Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

July 12th 2023

The FDA has accepted a supplemental biologics license application seeking the approval of zanubrutinib in combination with obinutuzumab in the treatment of adult patients with relapsed/refractory follicular lymphoma who received at least 2 prior lines of therapy.

LOTIS-9 Trial of Loncastuximab Tesirine/Rituximab in Untreated DLBCL Pauses Enrollment

July 11th 2023

ADC Therapeutics has voluntarily paused enrollment to the phase 2 LOTIS-9 trial investigating the combination of loncastuximab tesirine and rituximab for use in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.

Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSL

July 11th 2023

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Fixed-Duration Glofitamab Approved in Europe for Relapsed/Refractory DLBCL

July 11th 2023

The European Commission has granted conditional marketing authorization to glofitamab for fixed-duration administration in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic treatment.

NCCN Issues Guideline Update on the Use of High-Dose Methotrexate, Glucarpidase in ALL/B-Cell Lymphoma

July 6th 2023

The National Comprehensive Cancer Network has announced a guideline update concerning the treatment of patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric ALL, and pediatric aggressive mature B-cell lymphoma.

Glofitamab Monotherapy Produces Sustained Responses in Richter Syndrome

July 6th 2023

Administration of glofitamab after pretreatment with obinutuzumab provided encouraging antitumor activity with high and durable complete response rates and a manageable safety profile in heavily pretreated patients with Richter syndrome.

Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma

July 5th 2023

Treatment with the irreversible BTK inhibitor abivertinib led to responses and disease control in patients with relapsed/refractory marginal zone lymphoma.

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

June 28th 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Epcoritamab Elicits an ORR of 82% in Relapsed/Refractory Follicular Lymphoma

June 28th 2023

Epcoritamab elicited a confirmed overall response rate of 82% by independent review committee assessment in patients with relapsed or refractory follicular lymphoma who received 2 or more prior systemic treatments, which exceeded the prespecified threshold for efficacy in the phase 1/2 EPCORE NHL-1 trial.

Novel CD19xCD3 Bispecific Antibody May Expand Second-Line Options in Follicular Lymphoma

June 28th 2023

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27th 2023

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.